Last updated: July 17, 2026
Executive summary
Novartis Pharmaceuticals Corporation sued Accord Healthcare, Inc. in the District of New Jersey (case no. 1:22-cv-00431) alleging that Accord’s proposed FDA product submission infringes Novartis patents listed for a Novartis drug. The case is pending. Public docket filings available at the case level do not provide enough detail in the provided record to identify the asserted patents, the specific Novartis product, the paragraph IV posture, claim construction positions, claim charts, settlement terms, or whether any generic launch is at risk. Without those particulars, a complete litigation merits analysis cannot be produced.
What is the case background in Novartis v. Accord Healthcare 1:22-cv-00431?
Short answer: A patent infringement action filed by Novartis against Accord Healthcare in the District of New Jersey.
The case caption indicates:
- Plaintiff: Novartis Pharmaceuticals Corporation
- Defendant: Accord Healthcare Inc.
- Court: U.S. District Court for the District of New Jersey
- Docket: 1:22-cv-00431
What the docket record must show for an IP risk view
A litigation summary that supports enforcement and generic-entry decisions requires, at minimum, identification of:
- the FDA product/drug at issue,
- whether the suit is tied to an ANDA submission,
- the Orange Book-listed asserted patents (numbers and expiry),
- the theory (direct infringement, induced, contributory),
- and the timeline (complaint filing date, responsive pleadings, Markman, summary judgment, trial setting, settlement).
Those elements are not present in the provided information stream.
Which patents did Novartis assert against Accord Healthcare in 1:22-cv-00431?
Short answer: Not determinable from the provided record.
A defensible patent-estate analysis depends on the exact asserted patents and their families (composition, formulation, method-of-use, manufacturing, polymorph, process, or dosing regimens). Without the asserted patent list, the analysis cannot be completed without guesswork.
What drug and ANDA product are in scope for 1:22-cv-00431?
Short answer: Not determinable from the provided record.
A correct mapping from litigation to regulatory posture requires the docket’s linkage to the FDA submission:
- brand/generic pair,
- ANDA number,
- submission date,
- Paragraph IV notice date,
- and the specific dosage form and strength.
The provided docket-level identifier alone does not supply this.
What does the complaint allege: infringement theory and claim coverage?
Short answer: Not determinable from the provided record.
A merits-oriented litigation analysis requires at least one of:
- the list of asserted claims,
- the alleged infringing conduct (e.g., manufacture, use, sale, offer for sale, importation),
- Novartis’s infringement contentions (claim construction impacts, equivalent arguments),
- and whether Novartis sought preliminary relief (rare but critical for launch timing).
Those inputs are not available in the record provided here.
What is the procedural posture: motions, claim construction, and deadlines?
Short answer: Not determinable from the provided record.
A litigation progress analysis must cite:
- status of Motions to Dismiss,
- whether the court entered claim construction (Markman) findings,
- briefing schedule for summary judgment,
- and any case management orders affecting expert deadlines.
No such docket details were included in the provided information.
Has Accord challenged the asserted patents via invalidity or non-infringement arguments?
Short answer: Not determinable from the provided record.
For Hatch-Waxman cases, defendants typically plead:
- invalidity under 35 U.S.C. §§ 101, 102, 103, 112,
- lack of infringement given the proposed label/composition/process,
- prosecution history estoppel or non-equivalence (where doctrine of equivalents is relevant),
- or statutory defenses (depending on the patent type).
Without the answer, counterclaims, or invalidity contentions, no accurate analysis can be made.
When does exclusivity or patent expiration drive generic entry risk in this case?
Short answer: Not determinable from the provided record.
Entry-risk models require patent expiry and listed exclusivities for the specific product. Without the asserted patent list, this cannot be calculated.
What is the Paragraph IV posture for Novartis v. Accord in 1:22-cv-00431?
Short answer: Not determinable from the provided record.
A Paragraph IV analysis requires:
- the notice of certification and date,
- whether it is a certification to invalidity and/or non-infringement,
- and whether the suit was filed within statutory windows that affect 30-month stay.
Those facts are not present in the provided record.
Is there any settlement or consent judgment in 1:22-cv-00431?
Short answer: Not determinable from the provided record.
Settlement terms can control launch dates, market carve-outs, and design-around commitments. Without settlement docket entries, no conclusion can be drawn.
How does this dispute affect Accord’s launch and Novartis’ exclusivity strategy?
Short answer: Not determinable from the provided record.
The launch impact depends on:
- whether a 30-month stay is triggered,
- whether a preliminary injunction is sought and granted,
- the scope of any settlement carve-outs (e.g., NDC, strength, label language),
- and whether the asserted patents include “last-covering” patents.
None of those details exist in the provided record.
How strong is Novartis’ patent estate likely to be in 1:22-cv-00431?
Short answer: Not determinable from the provided record.
A strength analysis usually quantifies:
- number of asserted patents,
- remaining life at filing,
- patent family size and continuity,
- prior litigations for the same patents,
- prosecution history vulnerability,
- and known enablement/obviousness issues.
This requires patent numbers and claims.
How does this case compare with other Novartis v. generic filings in 2022?
Short answer: Not determinable from the provided record.
Comparative analysis requires:
- a list of parallel Novartis litigations (same drug),
- overlapping defendants, and
- shared asserted patents.
The provided input includes only one case identifier.
Key Takeaways
- Novartis Pharmaceuticals Corporation has filed a patent infringement action against Accord Healthcare in the District of New Jersey, case no. 1:22-cv-00431.
- The provided information is insufficient to identify the drug, asserted patents, ANDA/Paragraph IV posture, litigation milestones, or settlement status, so a complete litigation summary and decision-grade analysis cannot be generated from the given record.
FAQs
- What is the court’s standard schedule for Hatch-Waxman patent cases in the District of New Jersey?
- How do claim construction outcomes typically affect Novartis generic infringement wins or losses in ANDA litigations?
- What evidence usually drives non-infringement arguments in formulation and method-of-use patent cases?
- How is launch timing affected by 30-month stays and possible preliminary injunctions?
- What settlement structures are most common in Novartis generic patent disputes (design-arounds, carve-outs, payment-to-delay risk controls)?
References
- District of New Jersey docket: Novartis Pharmaceuticals Corporation v. Accord Healthcare Inc., No. 1:22-cv-00431.
